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Seeding of prostate cancer along a needle biopsy track is a rare complication. The diagnosis of this
presents a signiﬁcant upstaging of the disease and profound potential changes to the treatment strategy.
In this report, we present a 71 year-old male with otherwise low-risk prostate cancer on ﬁnal pathology
except for extraprostatic extension (EPE) along a probable needle track. We further review the relevant
literature regarding this rare but important complication with prostate needle biopsy.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Transrectal ultrasound-guided needle biopsy of the prostate
(TRUS-Bx) is a frequently performed procedure to diagnose pros-
tate cancer. While rare, it is possible that prostate cancer cells can
be displaced extraprostatically by the biopsy needle and subse-
quently proliferate. This iatrogenically-induced extraprostatic ex-
tensions can cause a diagnostic a dilemma regarding adjuvant
treatment. In this report, we present a patient with low-risk pros-
tate cancer who was found to have a single focus of extraprostatic
extension along a needle biopsy track.Case presentation
A 71 year old male was referred to our institution in 2008 for
management of prostate cancer after a single microscopic focus
of Gleason 3 þ 3 ¼ 6 prostate cancer was found on TRUS-Bx. At
the time, he had 3 prior negative prostate biopsies, his PSA was
2.7 ng/ml, and 14.7% free PSA. He was placed on expectant man-
agement and, in 2014, he underwent a prostate biopsy showing one
core of Gleason 3 þ 4 ¼ 7 involving 30% with perineural invasion.
He elected for radical retropubic prostatectomywith bilateral pelvic
lymphadenectomy. His postoperative course was unremarkable.
On ﬁnal pathology, his prostate was 97.9 g, with no palpable
nodules. There was a dominant tumor nodule of Gleason score
3 þ 3 ¼ 6 involving the right posterolateral region, extending from. Johnson).
Inc. This is an open access article uthe apex to the mid portion of the gland (Fig. 1A and B). The tumor
comprised approximately 1e2% of the total prostate gland volume.
Therewas a focal area of extraprostatic extension (EPE) identiﬁed in
a probable area of needle tract displacement in the right posterior
mid gland. Biopsy-site changes with a ﬁbrotic scar and
hemosiderin-laden macrophages were present in the area of EPE
(Fig. 1C and D). No seminal vesicle invasion by tumor was present,
and all margins were negative. In a bilateral pelvic lymphadenec-
tomy, all six lymph nodes were negative for tumor. The prostate
cancer was staged as a pT3a N0 with a note indicating that the area
of EPE was due to displaced carcinoma involving a needle tract.Discussion
Approximately 1 million prostate biopsies are performed
annually as a means of prostate cancer diagnosis or surveillance.1
Tumor seeding along the biopsy tract is a very rare but nonethe-
less reported risk.2 Bastacky et al reviewed a series of 350 prosta-
tectomy specimens from the Johns Hopkins Hospital, assessing for
extension of disease along a needle biopsy track. In this series, the
authors reported a 2% incidence of tracking, with an additional
3.7% being equivocally positive for extension along the needle
track.3 Volanis et al recently published a literature review of needle
track seeding during TRUS-Bx and identiﬁed 42 reported cases.4
The majority of these were older case reports using transperineal
biopsy and, unlike the patient in this report, the majority involved
poorly differentiated adenocarcinoma. Diagnosis was made by
biochemical recurrence, palpable nodule on DRE, perineal mass,
and incidental ﬁnding during colorectal surgery. The reported time
to disease recurrence was variable, from 1 month to 14 years.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Radical prostatectomy specimen with prostatic adenocarcinoma, Gleason score 3 þ 3 ¼ 6 shown in (A) with inﬁltrative well-formed small glands and adjacent benign
atrophic prostatic glands. At higher power (B), the tumor glands show abundant amphophilic cytoplasm, dense secretions, and prominent nucleoli. Extraprostatic extension in an
area of needle tract is demonstrated in (C) with tumor glands inﬁltrating beyond the contour of the prostate, seen in the same plane as adipose tissue. Abundant ﬁbrosis is seen
adjacent to these glands, forming a scar. Abundant hemosiderin-laden macrophages are seen in the vicinity of the scar at higher power (D), which is characteristic of biopsy-site
change.
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biopsy were deduced from post-prostatectomy recurrence rather
than by diagnosis of the prostate at time of surgical extirpation.
The rarityof tumorseedingalongabiopsy trackmakes itdifﬁcult to
identify risk factors. Needle type or size, biopsy approach (transrectal
vs. transperineal), or biopsy technique fail to show any increased
associated risk. Indeed, the number of biopsies needed to statistically
identify risk factors is prohibitively large. Although outside the scope
of this report, tumor seeding from prior tissue sampling has been
reported in many malignancies, genitourinary and otherwise.
The implication of tumor seeding along the needle track is po-
tential upstaging of prostate cancer from stage I to stage III. Adju-
vant radiation with or without hormonal therapy may be
considered, as it reduces metastases and improves survival in a
randomized trial of patients with pathologic T3 disease.5 However,
the must be counterbalanced with the side effects of incontinence
and impotence. With isolated extension along a needle track and
Gleason 3 þ 3 ¼ 6 disease, the reported patient opted for moni-
toring with early salvage therapy if he recurred biochemically. Fourmonths postoperatively, he was continent, regaining erectile func-
tion, and PSA was undetectable.
Conclusion
EPE of otherwise low-risk prostate adenocarcinoma along a
needle biopsy track is a rare ﬁnding. Adjuvant treatments for EPE
should be discussed with the patient, although the risks of adjuvant
therapy may outweigh surveillance with early salvage therapy.
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